These results implied that an underlying inflammatory state might play a role in resistance to systemic therapy or in increased tumor aggressiveness, thus supporting the conclusion of the present study that CRP was a possible biomarker predicting the efficacy of the mFOLFIRINOX regimen. The gene discussed is CRP; the disease is neoplasm.